Retatrutide: Triple Agonist Weight Loss Peptide

Triple Mechanism of Action

Retatrutide stacks three receptor pathways:

• GLP-1 receptor: Suppresses appetite, slows gastric emptying, improves insulin secretion
• GIP receptor: Enhances insulin response, improves fat metabolism, reduces GI side effects of GLP-1
• Glucagon receptor: Increases energy expenditure (metabolic rate), promotes fat oxidation in the liver

The glucagon component is the key differentiator. While glucagon alone raises blood sugar, in combination with GLP-1 its metabolic effects dominate — increasing calorie burn without significant glycemic impact.

Phase 2 Results vs. Competitors

Phase 2 data. Not head-to-head trials — populations and durations differ. Retatrutide not yet FDA approved.

Who Is a Candidate?

Retatrutide may be considered for:

• Patients who responded poorly or partially to semaglutide or tirzepatide
• Individuals with significant obesity (BMI 35+) who need aggressive intervention
• Patients with metabolic syndrome, NAFLD, or significant insulin resistance
• Those seeking the most aggressive pharmaceutical weight loss option available

Not FDA approved. Discuss the risk/benefit profile with your physician — available data is Phase 2 only.